Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : A Special Edition of Innovation2, brought to you by David and Jim Reese (Brothers2)

10/20/2021 | 01:52pm EST

It's safe to say that family dinners at the Reese household were never boring. Dr. David Reese, executive vice president of Research and Development at Amgen, and his brother Dr. Jim Reese, former Chief Operations Engineer and employee #18 at Google and current advisory board member for Harvard Medical School Department of Biomedical Informatics, recently met up virtually to discuss their upbringing, personal inspirations and motivations as part of the latest installment of Innovation2.

In the video, both brothers shared the challenges they faced and overcame in their professional careers. Jim shared stories from his early days at Google, including what it took to scale the site from one room of servers to the behemoth search engine that we know today. Similarly, Dave shared his experience taking on drug development for some of the toughest-to-treat diseases, how memories from his days as a medical oncologist motivates him and what it takes to organize the "highly disciplined and specialized army" it takes to bring a drug to market.

Innovation2 is a video series created by Amgen in collaboration with The Nation of Artists to highlight how some of the brightest minds think about innovation. The series sheds light on what fuels tenacity for today's innovators and how pushing against the status quo allows them to truly make a difference in the world. Each episode features one innovator from within Amgen and one innovator from another sector. The conversations are often inspiring and entertaining, highlighting personal contributions and today's cutting-edge science and innovation.

You can view David and Jim's episode below, and the rest of the series is available on Amgen's YouTube channel.

Disclaimer

Amgen Inc. published this content on 20 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 17:51:06 UTC.


ę Publicnow 2021
All news about AMGEN INC.
11/24Amgen To Present At The 2021 Evercore ISI Healthcare Conference
PR
11/24Amgen To Present At The 2021 Piper Sandler Healthcare Conference
PR
11/23AMGEN : In a First for Industry, Murielle Veniant-Ellison Honored With 2022 Havel Lectures..
PU
11/22AMGEN : Supporting Access to Nutritious Foods in Amgen's Community
PU
11/22WALL STREET STOCK EXCHANGE : Covid spike has many consequences on stock markets
11/22ANALYST RECOMMENDATIONS : Activision Blizzard, Amgen, Ebay, Vmware, Xcel Energy...
11/22Mizuho Securities Cuts Amgen's Price Target to $194 From $222, Citing 'Potential 2022 H..
MT
11/19BMO Capital Starts Amgen at Market Perform With $228 Price Target
MT
11/17AMGEN : A New Way to Connect Psoriatic Disease Patients with Healthcare Providers
PU
11/17Amgen Awards The Bath Institute of Rheumatic Diseases $25,000 Through UPLIFT Innovation..
PR
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 018 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 411 M - -
P/E ratio 2021 20,3x
Yield 2021 3,46%
Capitalization 113 B 113 B -
EV / Sales 2021 5,21x
EV / Sales 2022 4,89x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 201,09 $
Average target price 238,86 $
Spread / Average Target 18,8%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-12.54%113 267
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049